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1. Introduction 
According to data by GLOBOCAN, the worldwide incidence of colorectal cancer in 2008 
was 1,234,000 (with 663,000 male and 571,000 female cases). The number of deaths due to 
this disease was 608,000 (320,000 men and 288,000 women). Given these figures, colorectal 
cancer is the third and second leading cause of mortality among men and women. In the 
recent year in Hungary with a population around 10 million the annual incidence among 
males was 4,415, whereas the number of afflicted women was 3,690. Mortality data is similar 
with deaths among men and women being 2,563 and 2,190 respectively. Therefore, the 
disease is the second leading cause of death for both genders worldwide and in Hungary as 
well (Gaudi & Kásler, 2002; Ottó & Kásler, 2005; World Health Organization WHO – 
International Agency for Research on Cancer IARC, 2008). In international comparison 
Hungarian colorectal cancer mortality rates for 2008 were the highest in Europe for both 
men (31.4 per 100,000) and women (16.2 per 100,000). This is in striking contrast to 
comparable figures of Albanian men (6.2 per 100,000) and women (5.8 per 100,000), with the 
lowest registered numbers (WHO – IARC, 2008). Both frequencies of the disease and 
continuously improving treatment results highlight the accentuated place colorectal cancer 
takes in routine oncology practice and at the same time oblige health care services to 
provide the best possible treatment for patients. 
As a result of organizational efforts in the last decades to improve professional cooperation, 
leading to the development of new drugs and to a more conscious treatment planning with 
a closer to optimal use of combinations, metastatic colorectal cancer (mCRC) has become a 
chronic disease (Haller, 2007; Khan et al., 2008; Khan et al., 2010; Phillips & Currow, 2010; 
van der Velden et al., 2009; van Kleffen et al., 2004).  
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Today median survival of CRC-patients from the diagnosis of distant metastases can reach 36 
months on overall. Even in disseminated illness the chances of surviving more than five years 
are above 12% now (Blaser, 2010; Chau & Cunningham, 2009; Goldberg, 2007; Grothey, 2007; 
Michael & Zalcberg, 2000; National Cancer Institute NCI, n. d.; Sudoyo, n. d.)  
In 2004 Grothey and colleagues presented a diagram in the Journal of cilinical oncology 
which has been cited countless times ever since. The survival of mCRC patients was plotted 
on this diagram as a function of the proportion of patients treated with drug combinations 
considered "basic" (fluoropyrimidine, irinotecan, and oxaliplatin), and multiple linear 
regression was performed (Grothey et al., 2004) Based on the results it is clear that those the 
patients that had the greatest chance of survival who had received all three drugs during 
their treatment. Of course, it is not just "traditional" cytostatic remedies – antimetabolite 
fluoropyrimidines, the topoisomerase inhibitor irinotecan, and alkalizing agent oxaliplatin – 
that influence survival (Takimoto and Calvo, 2005). Based on new results, drugs aimed at 
biological targets do so, on their own and in different combinations with chemotherapy as 
well, which we will discuss later in detail. 
2. Biological targeted drugs 
2.1 Brief description of drugs affecting biological targets 
Drugs currently in use in this category can be classified into two major groups.  
A well known and characteristic representative of one of these groups is bevacizumab 
(Avastin®) (European Medicines Agency EMA, 2011a) inhibiting neoangiogenesis, i.e. this 
drug slows down the pathological vascularization of tumours and thus inhibits their 
provision of oxygen and nutrition.  
The other group consists of cetuximab (Erbitux®) (EMA, 2010) and panitumumab (Vectibix®) 
(EMA, 2011b), both influencing the effect of "epidermal growth factor receptors" (EGFR) 
located on the surface of tumours and in this way both interfere with the regulation of cell 
division and proliferation (Helbling & Borner, 2007; Mayer, 2009; Siena et al., 2009; Willet et 
al., 2007). 
These are all monoclonal antibodies. As a result of advances in manufacturing technology 
"chimeras" containing more non-human amino acid sequences (cetuximab – “cmab”) were 
followed by "humanized" antibodies like bevacizumab (“beva”) with increased proportion 
of human sequences within the molecule. The ultimate result of this process is the 
development of monoclonal antibodies containing exclusively human amino acid sequences 
(panitumumab – “pmab”). The ratio of human and non-human amino acid sequences 
within a given therapeutic antibody medication is crucial—the presence of the latter usually 
necessitates the use of saturating doses, while fully human substances can be administered 
using the same dose from the start of therapy. Human versus non human composition of 
complex protein molecules administered via infusion is also a key determinant of the 
frequency of infusion related and other side effects caused by "foreign proteins" (Eng, 2010; 
de Bono & Rowinsky, 2002; EMA, 2009; EMA, 2011a, b; Hochster, 2006; LoBuglio, 1989; 
Yang et al., 2001). 
2.1.1 Bevacizumab 
Generally used in combination with traditional cytostatic drugs, bevacizumab has been 
approved in Europe for many types of tumors: mCRC, breast cancer, clear cell renal cell 
www.intechopen.com
 Panitumumab for the Treatment of Metastatic Colorectal Cancer 
 
383 
carcinoma, and lung cancer (excluding planocellular or small cell carcinoma-types) (EMA, 
2011a). In addition, the U. S. Food and Drug Administration (FDA) has also approved its 
use in brain tumour recurrences following “traditional” treatment and in advanced brain 
tumour cases as well (glioblastoma multiforme) (U. S. Food and Drug Administration, 
2009).  
Beva binds to "vascular endothelial growth factor" (VEGF), one of the most important 
angiogenesis regulators. By doing this, beva inhibits the binding of VEGF to its receptors Flt-
1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. The neutralization of 
VEGF's biological activity lowers tumour vascularisation, normalizes the tumour's surviving 
vasculature and inhibits the development of a new vascular system for the tumour. By 
blocking tumour growth beva thus lowers intra-tumour pressure helping anticancer drug 
delivery to tumour tissue (Bergers & Benjamin, 2003; Borgstrom et al., 1999; EMA, 2011a; 
Folkman, 1971, Kim al., 1993). 
One of its main side effects is high blood pressure (usually successfully treated with ACE 
inhibitors, calcium channel blockers, or diuretics), and this usually does not necessitate 
ending or suspending the use of the drug. Therapy-resistant chronic hypertension however 
may mean a treatment contraindication. The frequency of proteinuria can vary considerably. 
Its severity can range from laboratory value deviations to development of nephritic 
syndrome. The severity of the detrimental side effect congestive heart failure can also cover 
quite a wide spectrum. Reduced left ventricle ejection fraction may ensue without any 
clinical symptoms but can be represented in a life-threatening form too. A wide variety of 
arterial and venous thromboembolic complications, as well as bleeding of any grade can 
occur. Bleedings may represent in the gastrointestinal system, primarily as perforations in 
patients with metastatic colorectal cancer treated with bevacizumab. Inflammatory intestinal 
diseases render patients especially susceptible to such perforations. Fistulae can also 
develop in different areas; perforations of the nasal septum are detected rarely. Reversible 
posterior leukoencephalopathy syndrome is a rare, neurological disorder which can also 
develop during beva treatment. Differential diagnosis can be challenging in such cases to 
rule out headaches, mental disorders, and possible cortical blindness frequently caused by 
cerebral metastases. (Allen et al., 2006; BC Cancer Agency Cancer Management Guidelines, 
2006; Benson et al., 2003; EMA, 2011a; Fakih & Lombardo, 2006; Giantonio et al., 2004; 
Hamilton, 2008; Kilickap et al., 2003; Martel et al., 2006; Pereg & Lishner, 2008; Scappaticci et 
al., 2007; Traina et al., 2006; van Heeckeren et al., 2007; Widakowich et al., 2007).  
2.1.2 Correlation between the therapeutic effect of EGFR inhibitor monoclonal 
antibodies (cmab and pmab) and K-ras mutation status 
Before presenting the mechanism of action of cmab and later that of pmab in details, it is 
necessary to understand the importance of EGFR status and K-ras mutation. Awareness of 
EGFR and K-ras mutation status has proven to be essential not only for an apt evaluation 
and interpretation of clinical trial results, but for adequate patient selection and diagnostics 
planning as well. A precise determination of both is a prerequisite for an effective treatment 
in everyday clinical routine. EGFR, a superficial structure of epithelial tumours and also 
CRC cells is a glycoprotein composed of three subunits. The exodomain receiving the ligand 
is outside the cell membrane, while the hydrophobic transmembrane domain provides 
proper cell membrane integration. The cytoplasmic “endodomain” is a catalytic subunit 
with tyrosine kinase activity. It transmits signals to other proteins by phosphorylating 
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messenger routes. In a complex mechanism, EGF activation initiates cell division following 
the reception of an adequate external signal. It also assures survival and inhibits apoptosis. 
The resulting effect is cell proliferation. While this mechanism is strictly controlled in 
healthy cells, EGF activation is uncontrolled in a considerable proportion of epithelial 
tumours. The signal is transmitted to other proteins via the biochemical route of tyrosine 
kinase by phosphorylation. EGF activation can initiate cell division, proliferation, 
development of metastases and inhibition of apoptosis. Apparently, this leads to tumour 
progression (Cohenuram & Saif, 2008; Coutinho & Rocha Lima, 2003; EMA, 2009; EMA 
2011b; Harari, 2004; Hamilton, 2008; Herbst & Shin, 2002; (Ritter & Arteaga, 2003; van 
Cutsem et al., 2009).  
EGFR inhibitors (cmab and pmab) are licensed for the treatment of mCRC patients. They 
bind to the extracellular ligand-binding domain and thus inhibit transmembrane signal 
transmission and prevent EGF dependent signal transduction within the cell as well. 
Although the mechanism of action has already been established in theory, EGFR inhibitors 
yield clinical improvement to not more than approximately 50% of mCRC patients. This 
observation led to the assumption that a biological factor could have prevented these 
monoclonal antibodies from being effective in tumours expressing EGFR. The K-ras 
(“Kirsten rat sarcoma 2 viral oncogene homolog”) gene belongs to the family of RAS proto-
oncogenes. The K-ras protein coded by this gene plays a central role in growth-inducing 
signal transmission routes. By doing so it affects cell reproduction, differentiation and 
survival. If a mitogenic signal reaches the EGF receptor, the signal is forwarded to the 
nucleus by the K-ras. It is essential that this close correlation applies only to the “normal” 
(i.e. non-mutated or “wild type”) K-ras. Mutant types of K-ras escape receptorial regulation 
and thus they autonomously stimulate cell proliferation.  
For this reason K-ras mutation is not a genetic failure with “function loss”, on the contrary, in 
this case RAS remains in “on” status (i.e. phosphorylation is continuous) and acts 
independently from EGFR (and other physiological signaling pathways). As a consequence, 
despite the signals reaching the cell surface being “blocked” by monoclonal antibodies at the 
receptor level, signaling tracks regulated by EGFR under normal conditions remain 
(chronically) activated (Amado et al., 2008; Benvenuti et al., 2007; Dahabreh et al., 2011; De 
Roock et al., 2010; (Engstrom et al., 2011a, b; Esteller et al., 2001; EMA, 2009; EMA 2011b; 
Hamilton, 2008; Heinemann et al., 2009; Malumbres & Barbacid, 2003; Normanno et al., 2009). 
As the estimated incidence of K-ras mutation in CRC is 30-50%, it is expected that in about 
half to two thirds of patients the regulation of signal effect and signal transmission are 
preserved and drugs acting via the K-ras route can be used with success. (Amado et al., 
2008; Benvenuti et al., 2007; Bardelli & Sien, 2010; Esteller et al., 2001; Garcia-Sáenz et al., 
2009; Malumbres & Barbacid, 2003; Nagasaka et al., 2004). In an interesting re-evaluation of 
their primary study population Hurwitz et al. found that though bev combined with IFL as 
a first line treatment of mCRC was effective in both K-ras wild type and mutant subgroups, 
efficacy was by large affected by K-ras status, underlining a mixed predictive and 
prognostic function of this mutation (Hurwitz et al., 2009). 
3. Characteristics, application and side effects of panitumumab 
3.1 Characteristics of panitumumab (Vectibix®) 
Pmab is a recombinant fully human monoclonal IgG2 antibody produced in a mammalian 
cell line (Chinese Hamster Ovary, CHO) by recombinant DNA technology. Vectibix has high 
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affinity and specificity to human EGFR. It inhibits receptor autophosphorylation caused by 
all known EGFR ligands by attaching to the ligand-binding domain. Binding of pmab to 
EGFR results in the internalization of the receptor, inhibition of cell growth, induction of 
apoptosis, and decreased interleukin-8 and vascular endothelial growth factor production 
(Berardi et al., 2010; EMA, 2011b; Harari, 2004; Helbling & Borner, 2007; Keating, 2010; 
Martinelli et al., 2007; Peeters et al., 2008; Pikó, 2009; Rakkar, 2007). 
3.2 Using Vectibix  
The recommended dose of Vectibix is 6 mg/kg of bodyweight once every two weeks both in 
monotherapy and when combined with cytostatics. Prior to infusion Vectibix should be 
diluted in 100 mL of 0.9% sodium chloride solution to a final concentration not exceeding 10 
mg/mL. Vectibix must be administered as an intravenous infusion via an infusion pump 
using a low protein binding 0.2 or 0.22 micrometer in-line filter through a peripheral line or 
indwelling catheter. The recommended infusion time is approximately 60 minutes (Alberta 
Health Services, 2010; EMA, 2011b). The first dose injected over 60 minutes was well 
tolerated in clinical trials where Vectibix was combined with cytostatic agents; subsequent 
treatments were allowed to be given over 30 minutes (Douillard et al., 2010; Peeters et al., 
2010). Doses higher than 1,000 mg should be administered as a 150 mL solution over approx. 
90 minutes. No incompatibilities have been observed with 0.9% sodium chloride injection in 
polyvinyl chloride bags or polyolefin bags (EMA, 2011b; Knudson, 2007). 
3.3. Side effects of panitumumab 
3.3.1 Skin toxicity 
The common pharmacological effect of EGFR inhibitors can lead to the following: EGFR 
inhibition in the skin, hair follicles, and periungual tissues can cause abnormal proliferation, 
migration and differentiation of target cells (i.e. basal keratinocytes), while changes in the 
skin structure attract inflammatory cells. Clinical symptoms emerge within 10 days 
following the introduction of pmab therapy and resolve in 28 days after the last injection on 
average. Skin symptoms are characteristic: papular skin rash, monomorphic pustular 
lesions, etc. presenting on skin areas exposed to the sun. Although signs may resemble those 
of acne for the first sight (labeled as “acneiform”), differentiation is easy and essential. Acne 
may manifest as non-inflammatory lesions on the basis of comedos or as inflammatory 
papules, pustules, or nodules. On the contrary, rash due to EGFR inhibitors is dominated by 
pustules. Non-inflammatory comedos are never seen in these cases. Skin rash is more 
widespread than classical acne as symptoms can often be observed on the upper and lower 
extremities and trunks of patients simultaneously. In order to prevent nail diseases it is 
important to avoid mechanical injuries (e.g. caused by tight shoes). Development of 
paronychia can be stopped by bathing the foot in diluted antiseptic agents and by using 
topical antiseptic ointments. Feet should not be soaked for a long time to prevent tissues 
from loosening. In some cases surgery cannot be avoided (Busam et al., 2001; Eaby, n. d.; 
EMA, 2011b; Moy & Goss, 2007; Pérez-Soler et al., 2005; Segaert & van Cutsem, 2005; 
Winkeljohn, 2008). 
Conventional modalities to treat acne should not be used. On the contrary, advices and 
interventions are usually completely different from those applied during acne therapy. Sun 
bathing is prohibited, patients should protect themselves from any direct sunlight (hat, 
long-sleeved clothes, and sun screens are recommended). Dryness of the skin should be 
treated with neutral emollients. Caution is warranted if topical steroid drugs are used. Such 
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products are recommended solely to alleviate symptoms. Systemic antihistamines are more 
useful to cure itching. If rash is accompanied by superinfection, external use of either 
clindamycin or mupirocin, or internal use of tetracycline are to be considered (Eaby, n. d.; 
EMA, 2011b; Hoda et al., 2008; Lacouture, 2009; Lacouture et al., 2010; Melosky et al., 2009; 
Moy & Goss, 2007; Peeters et al., 2008; Pérez-Soler et al., 2005; Pikó, 2009; Potthoff et al., 2011; 
Saif & Cohenuram, 2006; Winkeljohn, 2008). Efforts to deal with skin toxicities via pre-emptive 
approach (i.e. applying emollients, hydrating and photoprotective creams, topical steroids and 
oral doxycyclin) in the STEPP (“Skin Toxicity Evaluation Protocol With Panitumumab”) 
comparative clinical trial resulted in decreasing the frequency of Grade II or more severe forms 
already present from 62% to 28%. Quality of life improved significantly whereas the clinical 
efficacy of panitumumab treatment was unaffected. (Lacouture et al., 2010)  
 
 
Fig. 1. 66-year-old male patient’s acneiform rash after 2nd cycle (4th week) of pmab therapy 
for CRC with hepatic and pulmonary metastases.  
 
Fig. 2. Similar but more pronounced symptoms are visible on the back of the above patient.  
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Fig. 3. Clearly visible inflammatory signs (pustules) differentiate EGFR-inhibitor therapy 
related rash from classical acne.  
 
Fig. 4. Nail lesions (paronychia and overgrowth) developed on 6th week of pmab therapy. 
The disease did not resolve on conservative therapy, surgical treatment (exploration and 
drainage) was necessary. 
It is important to modify or discontinue pmab administration according to the stage of rash. 
If the adverse events to (U. S. Department of Health And Human Services, U. S. National 
Institutes of Health, National Cancer Institute – Common Terminology Criteria for Adverse 
Events NCI-CTCAE) Grade 3 skin lesions emerge Vectibix should be suspended until the 
lesions resolve to Grade 2 or lower. In this case the product can be used by a 50% dose 
reduction; the dose can then be increased to the original in 25% increments every two 
weeks. If the rash persists or the symptoms recur in spite of dose reduction, pmab should be 
definitively discontinued (Alberta Health Services, 2010; EMA, 2011b; Pikó, 2009; Potthoff et 
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al., 2011; Widakowich et al., 2007). Nevertheless, skin and nail lesions are usually considered 
as positive predictive markers of efficacy and clinical response (Amado et al., 2008; Berardi 
et al., 2010; Busam et al., 2001; Eaby, n. d.; EMA 2011b; Grothey, 2006, 2007; Keating, 2010; 
Malik et al., 2005; Martinelli et al., 2007; Saif & Cohenuram, 2006; Siena et al., 2009; 
Widakowich, 2007). 
3.3.2 Ophthalmologic complications 
Since marketing authorization rare cases of keratitis and ulcerative keratitis has been 
reported, both representing a consequence of general mechanism of action of EGFR 
inhibitors (EMA, 2009; Burtness et al., 2009; Specenier et al., 2007; Thomas & Grandis, 2004; 
Xu et al., 2009). Retrospective analyses have shown that these complications were not severe 
in clinical trials, i.e. they did not reach Grade 2-4 (U. S. Department of Health And Human 
Services et al., 2009), and their incidence was between 0.2% and 0.7%. In clinical use as 
monotherapy, another case of severe keratitis and three cases of severe ulcerative keratitis 
have been reported (EMA 2011b). Care must be taken when the patients has a record of 
keratitis or ulcerative keratitis in his/her medical history. Consultation with an 
ophthalmologist is necessary in any instances the following symptoms are presented: 
inflammation of the eye, increased lacrimation, sensitivity to light, blurred vision, pain or 
redness of the eyes. The diagnosis of keratitis allows the oncologist to weigh the risk/benefit 
ratio of continuing or stopping Vectibix therapy, in cases of ulcerative keratitis however 
pmab treatment should be discontinued or suspended (EMA, 2011b; ManageCRC.com. 
2011). 
3.3.3 Pulmonary complications 
Lung toxicity is a widely known complication of EGFR inhibitor therapies (interstitial lung 
disease ILD, interstitial pneumonitis, fibrosis) (Eaby, n. d.; Cohenuram & Saif, 2007; 
Gandara et al., 2006; Grothey, 2006; Inoue et al., 2003 ; Nagaria et al., 2005 ; Pikó, 2009 ; Saif 
& Cohenuram, 2006 ; Yoneda et al., 2007). 
As patients suffering from the above lung diseases were excluded from pmab clinical trials 
before randomization, there are no available data on lung complications in these patients 
during pmab therapy (EMA, 2011b). If patients experience chest symptoms (dyspnea, dry 
cough, clinical or ECG signs of hypoxia, abnormalities of pulmonary function tests), at least 
simple (posterior-anterior) chest radiography or a more appropriate chest CT should be 
performed. If these examinations are indicative of an interstitial pulmonary disease, Vectibix 
should be discontinued. Depending on the severity of symptoms, symptomatic treatment 
with corticosteroids or diuretics (NCI-CTCAE Grade 2), oxygen supplementation (Grade 3), 
or intubation, tracheostomy or assisted respiration (Grade 4) may be necessary (Alberta 
Health Services, 2010; Peeters et al., 2008; U. S. Department of Health And Human Services 
et al., 2009). 
It is important to differentiate pulmonary changes due to pmab therapy from signs of an 
underlying malignancy (e.g. well-defined metastases, carcinomatous lymphangiosis). 
Besides scrutinizing radio-morphologic features, other helpful measures, e.g. obtaining 
earlier radiographs, considering the dynamics of the process and sharing exact data with the 
radiologist (about the disease, signs, physical examination results, applied therapy) and 
further personal consultations may be appropriate as well and would underline the 
necessity of multidisciplinary oncological team-work. 
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Fig. 5. Chest CT taken before starting planned pmab therapy of a mCRC patient who 
received therapy earlier in another institution. As the scan revealed pulmonary infiltration 
we did not administer Vectibix. 
3.3.4 Hypomagnesaemia and hypocalcaemia 
Symptoms are caused by the renal effects of EGFR inhibitors. Pronounced EGFR expression 
can be detected in the renal parenchyma (primarily in the ascending limb of loop of Henle, 
where magnesium and calcium are absorbed). Inhibition of EGFR in the renal tissue causes a 
decrease in the serum magnesium and calcium concentration. Following the recognition of 
these phenomenon patients involved in pmab studies have had their serum magnesium 
levels assessed. In 39% of cases the result proved to be abnormal, most often indicating mild 
hypomagnesaemia. The “Summary of Product Characteristics” requires regular assessments 
of serum magnesium and calcium levels before the treatment starts and for at least 8 weeks 
thereafter. Appropriate substitution is necessary for patients with mild-moderate 
disturbances, but the treatment may be discontinued in those who do not respond to 
substitution or present with severe clinical signs. Other electrolyte changes, such as 
hypokalaemia, have been detected as well. In such cases appropriate electrolyte substitution 
must be the primary step (Eaby, n. d.; EMA, 2011b; Pérez-Soler et al., 2005; Peeters et al., 
2008; Pikó, 2009;, U. S. Department of Health And Human Services et al., 2009).  
3.3.5 Diarrhoea 
This is also a common side effect of EGFR inhibitors and indicates an injury of the intestinal 
mucosa similar to what is seen in dermatologic toxicities. Its frequency is not high; about 2% 
in patients with wild-type K-ras would develop diarrhoea. Its significance and its effect on 
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the continuability of pmab therapy depend on the severity of symptoms. Apart from 
lifestyle advices and loperamide administration, one should bear in mind that parenteral 
fluid replacement and normalization of electrolyte levels is essential in NCI-CTCAE Grade 3 
diarrhoea (defecation more than 7 times per day or fecal incontinence, or necessity of 
hospitalization due to symptoms). If one fails to do so, calcium and magnesium electrolyte 
disturbances may increase in severity and acute renal failure may also develop (Berlin et al., 
2007; Eaby, n. d.; EMA 2011b; Moy & Goss, 2007; Peeters et al., 2008; Pikó, 2009; Tuma, 2006; 
Widakowich et al., 2007). 
3.3.6 General symptoms and infusion complications 
Generally speaking, this term actually stands for adverse events (fever, chills and 
suffocation) which develop when a “foreign” protein is administered. Infusion 
complications emerge within 24 hours after administration. In most cases, premedication is 
needed to prevent general symptoms and infusion complications if human-animal chimeric 
or humanized monoclonal antibodies are used. As pmab is fully human, this is unnecessary 
when applying Vectibix. Nevertheless, infusion reactions might emerge during 
administration of fully human amino acid sequences despite using adequate protein filters 
to avoid complications. Several authors have reported however, that treatment with pmab 
may still be a viable and beneficial option for patients who suffered infusion reaction while 
being treated with the “chimeric” monoclonal antibody cetuximab (Cartwright & Genther, 
2008; Chung, 2008; EMA, 2011b; Grothey, 2006; Helbling & Borner, 2007; Heun & Holen, 
2007; Langerak et al., 2009; Lenz, 2007; Nielsen et al., 2009; O’Neil et al., 2007; Power et al., 
2010; Saif et al., 2008). 
Across all clinical studies, infusion-related reactions were reported in 3% of Vectibix-treated 
patients; of which < 1% were severe (NCI-CTC grade 3 or 4), i.e. required acute 
hospitalization or prolongation of hospitalization or was life-threatening. In the post-
marketing setting serious infusion reactions have been reported, including rare reports of 
fatal outcome. If a severe or life-threatening reaction occurs during an infusion or at any 
time post-infusion, Vectibix should be permanently discontinued (U. S. Department of 
Health And Human Services et al., 2009). 
4. Results of clinical studies with panitumumab 
4.1 Phase 1 studies 
At the Annual Meeting of the American Society of Clinical Oncology (ASCO) in 2002 Figlin 
and co-workers demonstrated the effect of a newly developed monoclonal antibody (called 
“ABX-EGF” in the presentation) on different tumors they evaluated in a phase 1 study 
(Figlin et al., 2002). The applied doses ranged from 0.01 mg/kg to 2.5 mg/kg. They found 
that the above therapy resulted in significantly long survival in certain cases. One patient 
with oesophageal cancer had stable disease for 7 months and minor response was reached in 
a patient with prostate cancer. No antibodies produced against ABX-EGF were detected, 
and its main side effect was rash. 
In 2004, Rowinsky and co-workers published their results from a Phase 1 study with ABX-
EGF (the agent later named pmab) used in renal cell carcinoma (Rowinsky et al., 2004). The 
highest dose used in this study was 2.5 mg per week. Although this dose could produce the 
highest rate of objective tumour response, the relationship between time to progression 
(median values were between 53 and 165 days) and the applied dose was unclear. It was 
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found that the most common side effects were dermatological symptoms (rash), already 
known in case of EGFR inhibitors. Presentation and severity of these symptoms were dose 
dependent and closely correlated with treatment results, while low haemoglobin and high 
alkaline phosphatase levels had a negative predictive value. No antibodies against ABX-
EGF have been detected in this study. 
4.2 Phase 2 studies 
Based on the analysis of early Phase 1 study results subsequent studies with pmab were 
conducted in mCRC patients. 
In 2004 and 2005 results of a phase 2 study with pmab monotherapy, involving CRC patients 
relapsing following a subsequent irinotecan and oxaliplatin therapy, were published (Hecht et 
al., 2004; Malik et al., 2005). Data of 148 patients were evaluable in the analysis. Median 
progression-free survival (PFS) was 3.4 (2.0-4.0) months and overall survival (OS) was 9.4 
months (6.0-10.6). Results did not differ in EGFR positive or negative patients. 
Berlin and co-workers (Berlin et al., 2004) and Hecht and co-workers (Hecht et al., 2006b) 
used pmab with combinations containing irinotecan (IFL or FOLFIRI) in Phase 2 studies. 
The main adverse effects were dermatological symptoms and diarrhoea. In the IFL arm 
partial remission fulfilling the “Response Evaluation Criteria in Solid Tumors” (RECIST) 
was seen in 48% of patients and stable disease could be reached in 26% that equated to a 
tumour control in 74% of cases (Jaffe, 2006; Padhan & Ollivier, 2001; Therasse et al., 2000). 
Median PFS and OS were 5.6 and 17 months, respectively. When pmab was used in 
combination with FOLFIRI rates of remission, stable disease and total tumour control were 
33%, 46%, and 79%, respectively. Progression-free survival was 10.9 months, but overall 
survival results could not have been calculated (overlapping results of the study had been 
published by other authors in various forums). 
Patients were later divided into groups with negative or “low” (1 to 10%) (Hecht et al., 
2006a), and “high” (above 10%) EGFR-expression (Berlin et al., 2006). No significant 
differences were found: at low EGFR levels 48% response rate and the rate 7.9 weeks 
median PFS were detected, while in patients with high EGFR levels 42% tumour response 
rate and 12-14 weeks PFS was seen. The adverse effect profile was similar. Grade 3/4 
adverse events were presented in 19-24% (dermatological symptoms prevailed), and the rate 
of hypomagnesaemia was similar (8 and 12%).  
4.3 Phase 3 study and analysis of further results  
Van Cutsem et co-workers were the first to publish a comparison of Vectibix and “best 
supportive care” (BSC): they treated a total of 463 patients with EGFR expressing mCRC, 
after failure of irinotecan- and oxaliplatin-containing therapies (van Cutsem et al., 2007). 
Patients were given either pmab (6 mg/kg every two weeks, without premedication) in 
combination (with symptomatic treatment) or BSC alone, in 1:1 ratio. Patients in the BSC 
group could have been switched to the active arm in case of progression. Thirty-five percent 
of patients had been on adjuvant chemotherapy earlier, and all of them had had at least two 
treatment options due to metastatic disease. Thirty-seven percent of the patients had a 
disease progression after the third line of drug therapy. Treatment efficacy was assessed 
after week 8, 12, 16, 24, 32, and 40, and every 3 months thereafter according to the RECIST 
(Jaffe, 2006; Padhan & Ollivier, 2001; Therasse et al., 2000). 
The following chart represents the results of this study and shows the benefits of Vectibix 
compared to supportive care: 
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Studied parameters pmab + BSC (232 patients) BSC alone (231 patients) 
PFS rate at week 24 18% 5% 
PFS rate at week 32 10% 34% 
Response rate (RR) 8% 0% 
Stable disease (SD) 28% 10% 
Overall response rate (ORR) 36% 10% 
Median duration of 
response 
17 weeks NA 
Table 1. Results of progression-free survival (PFS), response rate, stable disease, overall 
response rate treated with pmab + BSC vs. BSC alone (adapted from: van Cutsem et al., 
2007) 
In terms of all parameters (age, sex, site of primary tumour, ECOG performance status, 
former lines of chemotherapy applied, number of organs with metastases and degree of 
EGFR positivity), subgroup analyses unanimously showed that the active treatment arm 
(pmab) was superior to BSC. Degree of risk reduction was 46%, which was statistically 
significant (p<0.000000001). It is remarkable that among the 174 patients who were crossed 
over from BSC arm to the active (pmab) arm due to progression partial response (PR) could 
be reached in 9% and SD in 32% of cases, in spite of a more progressed disease (Cohenuram 
& Saif, 2007). 
This study once again proved the correlation between side effects and efficacy, i.e. 
assessment of the results showed that skin symptoms are of good predictive value. These 
findings underline the fact that rash is one of the most important predictive factors of 
efficacy.  
In the study designed to compare pmab and BSC, Siena and co-workers re-assessed 
response and survival data, and divided the group of responders into subgroups of patients 
with remission and those with stable disease. Differences between each group were 
statistically confirmed (Siena et al., 2007). Curves demonstrating treatment efficacy were 
also different, survival curve of patients with disease progression and that of those with no 
progression after 8 weeks of pmab therapy (equivalent with 4 treatment cycles) were 
compared. Based on these data the authors presumed with good reason that there must be 
another factor apart from the detectable EGFR expression (an inclusion criterion for all 
patients) that has an impact on treatment results.  
The presumed factor was later proved to be the K-ras mutation status. Differences in 
treatment results could be explained by the presence of “normal” (wild type) or “abnormal” 
(mutated) K-ras genes. Amado and co-workers determined the frequency of mutations in 
the already known patient population (Amado et al., 2008). Although not all, 427 samples of 
the 463 patients were suitable for subsequent central laboratory evaluations and were 
eventually analyzed. Analyses showed mutations in 184 patients and “wild type” K-ras in 
243 patients. Data analyses showed that no correlation can be detected between K-ras 
mutation and EGFR status (the latter determined by immunohistochemistry), neither by 
expression nor by the intensity of membrane staining.  
Analyses of clinical results showed that (in accordance with the biological role of K-ras 
described earlier) tumour progression in mutation carriers is independent from the 
regulation of stimuli reaching the EGFR. Consequently, in these patients the EGFR inhibitor 
pmab is less effective and does not provide better results than BSC.  
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 pmab + BSC BSC 








Number of patients 124 84 119 100 
Median PFS (weeks) 16 8 8 8 
Median OS (months) 8,1 7,6 4,9 4,4 
Table 2. Progression-free survival (PFS) and overall survival (OS) of pmab + BSC vs. BSC 
treated patients by K-ras status. (Source: Amado et al., 2008) 
Side effects were more frequent and severe in the K-ras mutant subgroup that, apart from 
inefficacy, may lead to a worse tolerability and possibly higher treatment risks. Considering 
both efficacy results and side effects, it was proven that pmab should only be used in 
patients with the wild type K-ras. 
4.4 Vectibix summaries of product characteristics: A reinforcement of treatment 
criteria and results of the clinical trials 
Based on the consideration that the approval had been based on a clinical trial including 
pre-treated EGFR positive patients whose treatment was shown to be effective only in those 
with the K-ras wild type, the European Medicines Agency (EMA) summarizes treatment 
criteria in all of the Summaries of Product Characteristics congruently. „Vectibix is indicated 
as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal 
carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, 
oxaliplatin-, and irinotecan-containing chemotherapy regimens” (EMA, 2011b). The U. S. 
Food and Drug Administration (FDA) defines the same criteria in more detail: „Vectibix is an 
epidermal growth factor receptor antagonist indicated as a single agent for the treatment of 
metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, 
oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free 
survival; no data demonstrate an improvement in disease-related symptoms or increased 
survival with Vectibix. Retrospective subset analyses of metastatic colorectal cancer trials have 
not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in 
codon 12 or 13. Use of Vectibix is not recommended for the treatment of colorectal cancer with 
these mutations” (U. S. Food and Drug Administration, 2009).  
5. Combining panitumumab with cytostatic agents 
The Summary of Product Characteristics of other anti-mCRC targeted biologic therapies 
states that these agents can be used either only in combination with “traditional” anti-
tumour chemotherapies (e.g. beva), or both in combination and as a stand-alone therapy 
(e.g. cmab). In contrast, pmab could only have been used as a monotherapy and in patients 
who have already had a definite cytostatic pre-treatment. Supposing that such timing of 
treatments does not provide optimal circumstances for the efficacy of monoclonal 
antibodies, possible combinations of Vectibix and cytostatic agents have been evaluated in 
clinical studies. 
5.1 Combination of pmab and chemotherapy as a first-line treatment 
Following completion of a study involving 1183 patients titled “Panitumumab Randomized 
Trial in Combination with Chemotherapy for Metastatic Colorectal Cancer to determine 
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Efficacy” (PRIME), Douillard and co-workers presented results of the application of pmab 
with FOLFOX4 (5-fluorouracil, leucovorin and oxaliplatin) versus FOLFOX4 alone as the 
first-line treatment in mCRC patients in open label, randomized, multicenter, Phase 3 trial 
(Douillard et al., 2010). Eligible patients were individuals older than 18 years who did not 
receive chemotherapy for their metastatic disease. 5-fluorouracil was allowed in adjuvant 
chemotherapy in case the disease recurred within 6 months after discontinuing the adjuvant 
therapy, but oxaliplatin was not allowed under any circumstances.  
Pmab was administered every two weeks in a dose of 6 mg/kg by intravenous infusion over 
one hour on the day before FOLFOX4 chemotherapy was scheduled. If patients tolerated the 
first pmab infusion, the consecutive doses could have been administered over 30 minutes. 
FOLFOX4 was administered every two weeks: on day 1 oxaliplatin was administered at 85 
mg/m2 and leucovorin at 200 mg/m2 (or equivalent dose) via infusion. On days 1 and 2 this 
was followed by fluorouracil at 400 mg/m2 by intravenous bolus and fluorouracil at 600 
mg/m2 by a continuous 22-hour infusion. This treatment was continued until disease 
progression (adjudicated by an independent committee) or the occurrence of unacceptable 
side effects. 
In terms of evaluation the study had four arms, as groups of K-ras mutant and wild-type 
patients were distinguished following previous laboratory assessment both in the FOLFOX4 
alone and the pmab + FOLFOX4 arm.  
The administration of the monoclonal antibody Vectibix to patients with wild-type K-ras 
increased PFS significantly from 8.0 to 9.6 months, while increase in overall survival (23.9 
months as compared to 19.7 months) was clinically considerable and relevant nevertheless 
statistically non-significant, compared to FOLFOX4 alone arm. In K-ras mutated cases 
however, Vectibix with FOLFOX4 versus FOLFOX4 alone decreased the median PFS (7.3 vs. 
8.8 months) and OS (15.5 vs. 19.3 months).  
By a glance on the table summarizing side effects one can realize that apart from typical side 
effects of EGFR inhibitors in the Vectibix group no significant differences were revealed. 
Antibodies against pmab were found in blood samples of 3.0% of patients (samples were 
drawn during treatment). After discontinuation, neutralizing antibodies were found in 
another 0.4% of patients. 
A forest plot subgroup analysis with overlapping confidence intervals showed that pmab 
addition was generally beneficial in terms of improving progression-free survival. 
Treatment without pmab showed a tendency to be more beneficial in those with bad 
performance status (ECOG 2). Pmab seemed to be more beneficial in those with hepatic 
metastases, however in patients with dissemination in multiple organs and in cases 
presenting exclusively hepatic metastases no significant differences between the arms were 
shown. Subgroup analyses of overall survival revealed similar results, notably, poorer 
general condition (ECOG 2) seemed to be again more disadvantageous for Vectibix treated 
patients, age and gender showed marked but somewhat weaker interference than is PFS.  
The authors claimed that adding pmab to FOLFOX4 increased PFS significantly in 
previously untreated mCRC patients with wild-type K-ras. Another clinically important 
feature of pmab is that severe infusion reactions are rare, and the standard 2-week protocol 
of Vectibix enables treating physicians to synchronize administration with chemotherapy 
schedules and decreases the number of visits to the minimum. As no premedication is 
required and no observation is necessary following treatment, the short outpatient therapy 
is advantageous for patients and caregivers as well. 
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An important aspect, also relevant for routine clinical practice, was investigated by Siena 
and co-workers in their subgroup analysis of the above study detailed in ASCO Annual 
Meeting 2011 (Siena et al., 2011). Patients with good performance status (ECOG 0-1) 
obviously profited from the addition of pmab to FOLFOX4 as PFS increased in these cases 
from 8.0 (7.5-9.3) to 10.4 months (9.3-11.3), OS from 20.7 (18.2-23.2) to 25.8 months (21.7-not 
estimable); whereas at ECOG2 (ambulatory and capable of all self-care but unable to carry 
out any work activities up and about more than 50% of waking hours) patients the addition 
a pmab decreased PFS from 7.6 (5.3-11.1) to 4.8 months (2.7-5.3), OS from 11.7 (8.0-15.7) to 
7.0 (4.6-11.7) months. An adequate determination of performance status may serve as a 
simple and statistically convincing tool to predict the value of the addition of pmab to 
FOLFOX4 in the first line treatment of mCRC. 
Notably, besides performance status, quality of life may be a further parameter worth 
evaluating when analysing treatment results. Primary results from a phase II study 
involving 142 patients evaluating the combination a pmab and FOLFIRI as a first line 
chemotherapy in mCRC were published by Kohne and co-workers in 2010 (Kohne et al., 
2010). Results showed 48% response rate (RR) for wild type and 29% RR for mutant K-ras 
patients, with no differences in side effects. Results of a secondary analysis of initial quality 
of life measures were published during ASCO Annual Meeting 2011 (Karthaus et al., 2011). 
The results demonstrated that those patients with better quality of life had better tumour 
responses as well by week 8 and 24 of the combination therapy. It does not seem to be an 
overstatement that the combination of pmab with cytostatics in the first line treatment of 
CRC is a promising option for patients in better clinical (performance and quality of life) 
status.  
5.2 Combination of pmab and chemotherapy as a second-line treatment 
Peeters and co-workers compared the efficacy of pmab and FOLFIRI to FOLFIRI alone as the 
second-line treatment of mCRC patients in a phase 3, equally randomized trial (Peeters et 
al., 2010). The study was originally designed to compare the therapeutic effect in the entire 
population, but due to convincing external data it was modified before the efficacy 
assessments so that prospective assessments would be carried out as per the K-ras status of 
the tumour. 
A total number of 1186 patients were treated after randomization. Five hundred-ninety-two 
(50%) patients were given pmab and FOLFIRI, and 595 (50%) were given FOLFIRI alone. 
The K-ras status of 1083 patients (91%) was known (based on central laboratory tests): 597 
patients (55%) had wild-type K-ras tumour and 486 (45%) had K-ras mutant metastatic colon 
cancer. 
The eligible patients were older than 18 years and their ECOG performance status was 0, 1 
or 2. Only one earlier chemotherapeutic scheme, i.e. first-line fluoropyrimidine-based 
chemotherapy was allowed for the treatment of mCRC. A radiologically verified 
progression by RECIST was required during the course of treatment or within 6 months. 
Known EGFR expression or K-ras status were not required for enrolment. Patients 
previously treated with irinotecan or anti-EGFR therapy were excluded from the study 
(Jaffe, 2006), (Padhan & Ollivier, 2001), (Therasse et al., 2000). 
Pmab (at 6 mg/kg) was administered over 60 minutes by infusion before chemotherapy; if 
patients tolerated the first dose, the following infusions were administered over 30 minutes. 
Every patient was given FOLFIRI: 180 mg/m2 irinotecan and 400 mg/m2 raceme leucovorin 
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(or 200 mg/m2 l-leucovorin) by intravenous infusion on day 1 and 400 mg/m2 fluorouracil 
by intravenous bolus on day 1, followed by 2400 mg/m2 by continuous infusion on days 1 
and 2. Patients were given chemotherapy with pmab or without pmab until the onset of 
progression or intolerance as per RECIST (confirmed by independent investigators) (Jaffe, 
2006), (Padhan & Ollivier, 2001), (Therasse et al., 2000). 
In terms of evaluation the study had four arms, groups of K-ras mutant and wild-type 
patients (as previously assessed) were distinguished both in the FOLFIRI (alone) and the 
pmab + FOLFIRI arm.  
PFS improved significantly in the subgroup of wild-type K-ras patients if pmab was added 
to chemotherapy; the median PFS was 5.9 and 3.9 months in the pmab + FOLFIRI and the 
FOLFIRI alone group, respectively. A non-significant increase in OS was also observed, 
median OS was 14.5 and 12.5 months, the response rate improved from 10% to 35% with 
added pmab. Theoretical assumptions and earlier clinical experiences were confirmed by 
the fact that no difference was seen in terms of efficacy in patients with K-ras mutant tumors 
compared to chemotherapy alone. 
Antibodies produced against pmab following therapy were found (by central laboratory) in 
less than 1% (4 out of 501) of patients. None of these antibodies had a neutralizing effect. 
Subgroup analysis suggests that pmab was advantageous in every subgroup in terms  
of improved PFS with a similar age and gender tendency as seen in the “PRIME” study.  
In terms of OS, combination arm seemed equivocal with chemotherapy alone in patients 
previously treated with oxaliplatin, beside those overlapping confidence intervals  
and summary measures favouring panitumumab reinforced a positive tendency of 
improving OS.  
The authors claimed that the study confirmed the efficacy of pmab with FOLFIRI in K-ras 
wild-type mCRC patients who were treated previously. PFS improved in a statistically 
significant manner in this group, which underlines the fact that K-ras status of the tumour 
can be considered as a predictive biomarker. With a Q2W administration, pmab was 
comfortably combined with FOLFIRI given at a similar dosing frequency. The toxicity 
profile was not different from that of EGFR inhibitors and chemotherapy combinations, 
toxicities could have been managed well.  
Considering that, in Hungary bevacizumab is reimbursed only as a first line treatment by 
the state health fund - even though its use is not confined to a given line in mCRC by the 
effective Summaries of Product Characteristics (EMA, 2011a). Peeters and co-workers 
published data of critical relevance in ASCO Annual Meeting 2010 in this aspect (Peeters et 
al., 2010). The authors evaluated K-ras wild type patients from the above study previously 
treated with bevacizumab. According to the results, PFS was not different in bev pre-treated 
patients compared to the overall K-ras wild type study population (5.8 and 3.7 months vs. 
5.9 and 3.9 months for pmab + FOLFIRI and FOLFIRI arms). In striking contrast OS 
improved when bev treatment preceded the pmab + FOLFIRI combination in second line 
from 14.5 months to 15.7 months. 
6. Panitumumab in current therapeutic guidelines 
6.1 Pmab in U. S. guidelines 
From among clinical recommendations issued in the United States the first to review is the 
National Comprehensive Cancer Network’s (NCCN) guidelines referring to the diagnosis 
and treatment of colon (Version 3.2011) and rectal carcinoma (Version 4.2011) (Engstrom et 
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al., 2011a, b). As the results of clinical studies with pmab concern distant metastatic diseases 
only, there is no significant difference between the two compilations. Like other agents 
affecting biological targets pmab is not allowed in any adjuvant indication except for clinical 
trials. Pmab is recommended in monotherapy or in combination with FOLFIRI in diseases 
with distant metastases whether or not resection of the primary malignancy was performed. 
It is considered reasonable to remove the primary malignancy (which has not been removed 
earlier) and the distant metastases in one or more surgeries following a 2- to 3-month 
treatment. (It is strongly highlighted in the recommendation, that K-ras evaluation must be 
performed and that the product should be administered only in patients with the wild type 
K-ras.) In non-resectable synchronous or metachronous distant metastases FOLFIRI  pmab 
is an alternative of FOLFIRI  bevacizumab or cetuximab as a first-line therapy at least 12 
months after the administration of adjuvant FOLFOX.  
In patients eligible for intensive treatment, pmab  FOLFOX is considered as the first-line 
therapy of metastatic diseases (among other combinations), while pmab  FOLFIRI acts as a 
second-line therapy. Monoclonal antibody panitumumab is indicated as monotherapy in 
case the patient has decreased chemotherapy tolerance. Biological targeted agents such as 
pmab (depending on the previously administered agents) can be administered following a 
new progression (i.e. as a third treatment possibility), mostly in patients who do not tolerate 
irinotecan. Vectibix is recommended as a monotherapy by NCCN in patients who are 
ineligible for intensive therapy. 
6.2 Pmab in european guidelines 
The European Society for Medical Oncology (ESMO) released guidelines in 2010. Pmab is 
not mentioned in the publications referring to the diagnosis, adjuvant therapy and follow-
up of CRC (Labianca et al., 2010). This is compliant with the European Summary of Product 
Characteristics, which limits treatment possibilities much rigorously than the guidelines in 
the United States do. In guidelines detailing the treatment of advanced disease authors state 
(van Cutsem et al., 2010) that anti-EGFR antibodies pmab and cmab are effective as 
monotherapy for patients with chemorefractory mCRC, and wild-type state of K-ras is 
necessary to reach therapeutic effect. In comparison with BSC, pmab is considered beneficial 
in terms of PFS; this effect is not reflected in terms of overall survival (OS) due to the “cross-
over” design of trials. Pmab and polychemotherapy (FOLFOX4 as a first-line, and FOLFIRI 
as a second-line therapy) but the absence of significant improvement in OS is emphasized. 
Evidence level of all recommendations for pmab therapy is IB.  
7. Summary 
Being a fully human monoclonal antibody not requiring a special pre-treatment or 
saturation dosage, pmab belongs to a new group of biological targeted agents used in the 
treatment of metastatic colon or rectal cancer. Pmab binds to EGF receptors, and the post-
study pathologic evaluation of monotherapy registration trial samples provided convincing 
evidence of the crucial role K-ras status played in clinical efficacy: median progression-free 
survival was 16 weeks in the wild-type (vs. 8 weeks with best supportive care) patients 
group. Although pmab was practically ineffective in patients with mutant K-ras, side effects 
were more frequent and severe. According to effective Summaries of Product Characteristics 
the product can be applied in Europe as monotherapy in EGFR positive and K-ras wild-type 
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mCRC patients after fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapeutic 
protocols had failed.  
Based on clinical study results published in 2011, the addition of panitumumab to FOLFOX4 
polychemotherapy as a first-line treatment in wild-type K-ras resulted in a significant 
increase in progression-free survival (PFS) (8.0 to 9.6 months), while increase in overall 
survival (OS) (19.7 to 23.9 vs. FOLFOX4 alone) was clinically considerable but non-
significant. In K-ras mutant cases however, Vectibix with FOLFOX4 versus FOLFOX4 alone 
decreased the median PFS (8.8 to 7.3 months) and OS (19.3 to 15.5 months). PFS improved 
significantly in the group of wild-type K-ras patients if pmab was added to the FOLFIRI 
protocol as a second-line treatment; median PFS was 5.9 and 3.9 months in the pmab + 
FOLFIRI and the FOLFIRI alone groups, respectively. A non-significant increase in OS was 
also observed; median OS was 14.5 and 12.5 months, and response rate significantly 
improved from 10% to 35% with added pmab. In mutant K-ras, PFS was 5.0 months with 
added monoclonal antibodies and 4.9 months with FOLFIRI alone, while OS was 11.8 and 
11.1 months, respectively, i.e. no difference could have been statistically confirmed. 
Following a positive EMA’s Committee for Medicinal Products for Human Use (CHMP) 
opinion in the middle of 2011, both the FOLFOX4 (1st line) and the FOLFIRI (2nd line) 
combinations will be likely authorized in the EU for the treatment of mCRC. 
The side effect profile matches other EGFR inhibitors (the spectrum as a whole being utterly 
different from that of conventional cytostatics), with dermatologic symptoms (rash), nail 
diseases, lung infiltration, diarrhoea and electrolyte disturbances of renal origin may 
develop. Infusion complications are not common. Panitumumab therapy is safe in cases 
where followed-up carefully, this may mean temporary suspension of treatment, dose 
reduction or therapy discontinuation if justified by above detailed side effect related signs 
and symptoms.  
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